Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not.
about
The treatment of chronic depression with cognitive behavioral analysis system of psychotherapy: a systematic review and meta-analysis of randomized-controlled clinical trialsTreatment of chronically depressed patients: a multisite randomized controlled trial testing the effectiveness of 'Cognitive Behavioral Analysis System of Psychotherapy' (CBASP) for chronic depressions versus usual secondary care.Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents.Social problem solving and depressive symptoms over time: a randomized clinical trial of cognitive-behavioral analysis system of psychotherapy, brief supportive psychotherapy, and pharmacotherapy.Joining the dots: neurobiological links in a functional analysis of depression.The promise of cognitive behavior therapy for treatment of severe mental disorders: a review of recent developments.Treatment strategies to improve and sustain remission in major depressive disorder.The epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related ConditionsPatient preferences for treatment of major depressive disorder and the impact on health outcomes: a systematic review.An investigation into the effects of cognitive behavioral therapy on patients with chronic depression: a small case series.Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP TrialEmerging treatments for depression.Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy.Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments.Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptomsThe implications of gene-environment interactions in depression: will cause inform cure?The moderation of an early intervention program for anxiety and depression by specific psychological symptomsThe long-term course of depression: development of an empirical index and identification of early adult outcomes.Clinical inertia in depression treatment.Therapeutic armamentarium for treating depression.Four potential criteria for deciding when to use antidepressants or psychotherapy for unipolar depression: a literature review.Research on psychotherapy integration: building on the past, looking to the future.SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL.Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder.Patient preference compared with random allocation in short-term psychodynamic supportive psychotherapy with indicated addition of pharmacotherapy for depression.Four Reasons Why Assisted Dying Should Not Be Offered for Depression.Are Sensory Processing Features Associated with Depressive Symptoms in Boys with an ASD?
P2860
Q26744262-DE579FA5-350C-4B2C-9065-72240436657BQ33325739-8E848B7C-8A97-4046-A3FA-07A083C4183CQ33667966-58CFDC38-28C1-43E3-BE73-B98914011934Q33875563-88BC9AB7-8F65-4E33-B3E6-8D5D65AA23EBQ34439165-C8C2AD40-3AE8-4EEA-A4D6-945399CDFA0FQ34447066-24BDD618-0C28-42C8-8835-18ED676A0315Q35237047-E4232898-501A-42A8-99F0-6F214A7B710CQ35458096-6BE155E9-2DCE-48A7-8615-AE83B70ABDDBQ35702981-9C540E75-4107-469E-BEE1-CFD2B29ACE05Q36296942-33760D55-611C-4A60-8CBA-2752BB098A66Q36439957-5B632C28-654A-473B-84C1-65233BB61B90Q36655168-B570ACDA-14AC-46E2-948F-B054FB200996Q36984391-2E9D90A2-CAE5-4F41-B0DF-05C70B9DE303Q37197221-CA0093C7-2B08-4A1D-9125-4C1E8F7FB87DQ37208565-94E061CA-6FF6-41C6-8579-797B92A6083FQ37235032-9527E431-39B3-48AD-A4CF-359543FFA892Q37258945-13E40669-99C8-416D-9F8C-711E363CE56EQ37347988-7C6A00E2-F776-4DC3-BE4F-5FC3BC0B2EA3Q37730896-08F2482E-1252-4B6A-89FE-BA6C0B0E1FECQ37777008-F43A83AE-C5B8-419B-8C1E-479FD4EE5713Q37961995-74F1A2A5-397E-40CB-B541-9264F788C326Q38387903-49ABCD5E-9F57-4A86-B957-1B699D850D57Q38398475-1DA2E5D5-3E31-4BB6-A816-4A8064BFC2F9Q38740805-4FFC2B60-4AC5-4F39-A4D6-913FB9D5EA49Q46035603-F28EF2B8-C924-4AE2-8CAE-F9946611BBBBQ47320935-50604EA5-E732-4F92-806D-321161FA0FB7Q50345822-7DBB844E-26B7-434E-9972-94D5A5810369
P2860
Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Chronic depression: medication ...... fective when the other is not.
@en
Chronic depression: medication
@nl
type
label
Chronic depression: medication ...... fective when the other is not.
@en
Chronic depression: medication
@nl
prefLabel
Chronic depression: medication ...... fective when the other is not.
@en
Chronic depression: medication
@nl
P2093
P50
P1433
P1476
Chronic depression: medication ...... fective when the other is not.
@en
P2093
A John Rush
Alan F Schatzberg
Barbara O Rothbaum
Bruce A Arnow
Daniel N Klein
Frances E Borian
Ivan Miller
James H Kocsis
Janice A Blalock
John C Markowitz
P304
P356
10.1001/ARCHPSYC.62.5.513
P407
P577
2005-05-01T00:00:00Z